Lexeo Therapeutics investigational gene therapy for PKP2-related arrhythmogenic cardiomyopathy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Lexeo Therapeutics investigational gene therapy for PKP2-related arrhythmogenic cardiomyopathy, covering 2025-11-12 to 2025-11-12. Get the full timeline:
Most recent: Clinical Trial Update: Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant